TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27750353
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment in Ward-B
Study: 24667938
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral tenofovir
Study: 15050085
Drug: Combined psychotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined psychotherapy and pharmacotherapy for depression
Study: 10652955
Drug: Pamidronate (APD)
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pamidronate (APD) 30 mg i.v. in 500 ml D5W over 4 hours
Study: 9284985
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with extracts of Dermatophagoides pteronyssinus (Dpt) or D. farinae (Dfa) (Alutard SQ, ALK, Denmark)
Study: 24521021
Drug: calcineurin inhibitor
Normalized name: Calcineurin inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: calcineurin inhibitor
Study: 23750536
Drug: Glutamate supplement
Normalized name: glutamate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glutamate supplement + carbohydrate drink (GLU+CHO)
Study: 23750536
Drug: Glutamate supplement
Normalized name: glutamate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glutamate supplement + placebo drink (GLU)
Study: 23750536
Drug: Placebo supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplement + carbohydrate drink (CHO)
Study: 23750536
Drug: Placebo supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplement + placebo drink (CON)
Study: 18609122
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg ranitidine as a bolus intravenously
Study: 14697932
Drug: Cap Arpimune
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cap Arpimune ME (test formulation)
Study: 14697932
Drug: Cap Sandimmune
Normalized name: cyclosporine Oral Capsule [Sandimmune]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cap Sandimmune Neoral (reference formulation)
Study: 3924617
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin system (TNS) 20 cm2 or greater
Study: 3924617
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin system (TNS) 10 cm2
Study: 29954713
Drug: 3 weekly
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 weekly stage-tailored messages on healthful behaviors for 10 weeks; and 3 monthly stage-tailored messages and 1 monthly e-mail encouraging a visit to the portal page after the 3-month physical assessment
Study: 26784939
Drug: Talinolol 50
Normalized name: talinolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talinolol 50 mg tablet (oral administration)
Study: 26016363
Drug: Ligustrazine treatment
Normalized name: ligustrazine
DrugBank: Ligustrazine (DB19074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ligustrazine treatment (80 mg/d; i.v.; for 2 weeks) in addition to standard treatment
Study: 26016363
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with antibiotics, antiasthmatic and expectorant medications, and oxygenation
Study: 21862953
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with intravitreal ranibizumab and topical bromfenac
Study: 11125353
Drug: Temporary inactivation
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temporary inactivation of sacral nerve stimulation therapy
Study: 9743652
Drug: Combination Treatment
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Treatment (TPs and scanner technique)
Study: 8170098
Drug: Peribulbar anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peribulbar anesthesia (PERI) with 6, 8 or 10 ml of bupivacaine-lidocaine-hyaluronidase mixture
Study: 8170098
Drug: Retrobulbar anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrobulbar anesthesia (RETRO) using Unsold technique with 5 ml of bupivacaine-lidocaine-hyaluronidase mixture and Nadbath/Rehman facial nerve block (5 ml etidocaine-lidocaine mixture)
Study: 28929560
Drug: Minocycline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (10 mg/kg intravenous)
Study: 26518774
Drug: Housing First
Approvals — FDA: no, EMA: no, PMDA: no
Description: Housing First plus Assertive Community Treatment
Study: 22235821
Drug: Furosemide (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (60 mg)
Study: 22235821
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of furosemide and hydrochlorothiazide
Study: 17131317
Drug: antiCagA antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: antiCagA antibodies
Study: 17131317
Drug: Severe chronic
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Severe chronic atrophic gastritis (SCAG) defined as PGA <22 microg/l
Study: 15878384
Drug: Generic warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic warfarin sodium product
Study: 15878384
Drug: Branded warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded warfarin sodium product
Study: 12186116
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (Insulin only, 50 patients)
Study: 12186116
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (Insulin + GBC 20 mg/day, 49 patients)
Study: 12186116
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (Morning insulin + GBC 20 mg/day, 43 patients)
Study: 12186116
Drug: Group D
Normalized name: Prostaglandin group D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D (Evening insulin + GBC 20 mg/day, 46 patients)
Study: 1773076
Drug: Air caloric
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air caloric irrigation at 8 L/min for 45 seconds
Study: 1773076
Drug: Air caloric
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air caloric irrigation at 8 L/min for 60 seconds
Study: 1773076
Drug: Air caloric
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air caloric irrigation at 8 L/min for 75 seconds
Study: 1773076
Drug: Air caloric
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air caloric irrigation at 8 L/min for 10-beat and 10-sec measurements
Study: 6752558
Drug: Protocol A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol A: 6‐MP (50 mg/m2) p.o. daily + MTX (20‐30 mg/m2) p.o. weekly
Study: 6752558
Drug: Protocol B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol B: 6‐MP (50 mg/m2) p.o. daily + MTX (75‐150 mg/m2) i.v. every two weeks
Study: 6752558
Drug: Protocol C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol C: 6‐MP (50 mg/m2) p.o. daily + alternating 8‐week-courses of four biweekly i.v. injections of MTX (75‐150 mg/m2) and four biweekly i.v. injections of Cyclo (600 mg/m2)
Study: 31432689
Drug: Neratinib-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neratinib-based therapy
Study: 26027861
Drug: 0.2 ml
Normalized name: isopropyl alcohol 0.2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 ml 0.8% Hyaluronic Acid (HA) applied immediately after surgery
Study: 26027861
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment applied)
Study: 23044704
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) - 1000 shots at maximal tolerable intensity
Study: 23044704
Drug: Local corticosteroid
Normalized name: Corticosteroids acting locally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local corticosteroid (CS) injection
Study: 19851160
Drug: Injection phase
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection phase
Study: 17069488
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) with 685-nm wavelength, output power of 50 mW, energy density of 4 J/cm².
Study: 2528969
Drug: zidovudine 600
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: zidovudine 600 mg/day for 18 weeks
Study: 2528969
Drug: zidovudine 900
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: zidovudine 900 mg/day for 9 weeks
Study: 2528969
Drug: zidovudine 1200
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: zidovudine 1200 mg/day for 9 weeks
Study: 2528969
Drug: zidovudine 1200
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: zidovudine 1200 mg/day or highest tolerated dose at 8-hourly intervals after washout
Study: 2528969
Drug: zidovudine 600
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: zidovudine 600 mg/day
Study: 2528969
Drug: zidovudine 900
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: zidovudine 900 mg/day
Study: 2528969
Drug: zidovudine 1200
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: zidovudine 1200 mg/day
Study: 1252882
Drug: Cotrimoxazole 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimoxazole 2 tablets twice daily
Study: 1252882
Drug: Cephalexin 1
Normalized name: cephalexin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin 1 g twice daily
Study: 25263498
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of ampicillin and metronidazole
Study: 25263498
Drug: Multiple-day regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-day regimen of ampicillin/amoxicillin and metronidazole
Study: 22072853
Drug: Activated Dimethicone
Normalized name: Activated dimethicone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated Dimethicone plus water (up to 100 mL)
Study: 22072853
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) plus water (up to 100 mL)
Study: 22072853
Drug: Activated Dimethicone
Normalized name: Activated dimethicone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated Dimethicone and NAC plus water (up to 100 mL)
Study: 22072853
Drug: Water alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water alone (100 mL)
Study: 19153339
Drug: Topical tretinoin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tretinoin, 0.1%, applied twice daily to the face and ears
Study: 19153339
Drug: Vehicle control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control cream, applied twice daily to the face and ears
Study: 12770652
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of nifedipine intranasally delivered
Study: 8886294
Drug: Cocaine hydrochloride
Normalized name: Cocaine Hydrochloride
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine hydrochloride 0.3 mg/kg intravenously
Study: 2552868
Drug: Dexamethasone isonicotinate
Normalized name: Dexamethasone isonicotinate
DrugBank: Dexamethasone isonicotinate (DB11487)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone isonicotinate (four puffs bid for seven days, ie, 0.5 mg bid for seven days; last four puffs 30 minutes before TDI)
Study: 31739245
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine (2 μg·kg-1·min-1)
Study: 21705157
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection (3 mL)
Study: 21705157
Drug: Autologous blood
Normalized name: Banked autologous blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous blood injection (3 mL)
Study: 21705157
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (3 mL)
Study: 9311397
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (received allogeneic red cells if hemoglobin < 5 mmol/L)
Study: 8456428
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of hirulog (0.6 mg kg-1 h-1 for 2 h)
Study: 8456428
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of hirulog
Study: 8456428
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of hirulog
Study: 8456428
Drug: Intravenous hirulog
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hirulog
Study: 26924770
Drug: Targeted therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapies for metastatic renal cell carcinoma
Study: 22340541
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (0.2 g/kg) and soybean oil (1.0 g/kg)
Study: 22340541
Drug: Soybean oil
Normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean oil (1.2 g/kg)
Study: 1674231
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of roxatidine acetate at night
Study: 6223699
Drug: Etodolac (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac (mean daily dose: 319 mg)
Study: 6223699
Drug: Aspirin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (mean daily dose: 4,701 mg)
Study: 24329972
Drug: Extended cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended cognitive behavioral therapy
Study: 24329972
Drug: Standard cessation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cessation treatment without extended cognitive behavioral therapy
Study: 24329972
Drug: Extended nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended nicotine replacement therapy
Study: 15270789
Drug: Pioglitazone (initially
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (initially 30 mg QD, titrated to 45 mg)
Study: 15270789
Drug: Glibenclamide (initially
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (initially 1.75 mg QD, titrated to 10.5 mg)
Study: 11172962
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 10 x 3 Gy (total dose, 30 Gy) in 2 series (5 x 3Gy) separated by 8 weeks
Study: 11172962
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 7 x 3 Gy (total dose, 21 Gy) in 1 series within 2 weeks
Study: 8083702
Drug: Investigational therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational therapies in adjuvant therapy RCTs (14 of 90 RCTs)
Study: 8083702
Drug: Investigational therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational therapies in advanced-disease therapy RCTs (3 of 141 RCTs)
Study: 8083702
Drug: Dose-intensity with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-intensity with blood-product support trials
Study: 28082211
Drug: Glycerin suppositories
Normalized name: Glycerin Suppositories
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerin suppositories every 8 hours during phototherapy
Study: 28082211
Drug: No glycerin
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No glycerin suppositories (sham group)
Study: 19655226
Drug: Glycerin suppositories
Normalized name: Glycerin Suppositories
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerin suppositories
Study: 18768369
Drug: Anastrozole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1 mg/day for 5 years)
Study: 16361368
Drug: Phytoestrogens (resveratrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytoestrogens (resveratrol and genistein) and selective estrogen receptor-alpha agonist (PPT)
Study: 30067289
Drug: Telemetric gas-sensing
Normalized name: Kaolin 45.5 g in 130 g TOPICAL CREAM [SONATURAL THE PURE PORE TENSING CARBONIC BUBBLE POP CLAY MASK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemetric gas-sensing capsule (1.25-40 g inulin)
Study: 30067289
Drug: Telemetric gas-sensing
Normalized name: Kaolin 45.5 g in 130 g TOPICAL CREAM [SONATURAL THE PURE PORE TENSING CARBONIC BUBBLE POP CLAY MASK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemetric gas-sensing capsule (20 or 40 g glucose)
Study: 25948727
Drug: IV bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV bolus injection of 2.0 mg/kg cyclosporine
Study: 23418886
Drug: Web-based guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based guided self-help course (6 weekly lessons with weekly support from a coach)
Study: 23418886
Drug: Care-as-usual (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Care-as-usual (no additional treatment)
Study: 18254985
Drug: Carrot juice
Normalized name: carrot juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carrot juice (330 ml per day for 2 weeks)
Study: 18254985
Drug: Tomato juice
Normalized name: TOMATO JUICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato juice (330 ml per day for 2 weeks)
Study: 12843036
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of staphylococcal plasmid encoding multiple antibiotic resistance traits
Study: 10374223
Drug: Initial gestagen
Normalized name: Betagen brand of Betamethasone and Gentamicin Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial gestagen treatment (5 mg medroxyprogesterone acetate, twice daily, for 10 days)
Study: 10374223
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined hormone replacement therapy without initial gestagen treatment
Study: 10374223
Drug: Initial gestagen
Normalized name: Betagen brand of Betamethasone and Gentamicin Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial gestagen treatment
Study: 8708877
Drug: Behavioral intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioral intervention (6-week group treatment providing nutritional education and management strategies)
Study: 2065411
Drug: No alfentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: No alfentanil administered (Group 4)
Study: 31982887
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of monochromatic 308-nm excimer light (MEL) and topical calcipotriol
Study: 31982887
Drug: Topical calcipotriol
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical calcipotriol alone
Study: 31982887
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MEL and topical calcipotriol
Study: 29960800
Drug: MenACWY-TT and
Normalized name: meningococcal conjugate quadrivalent, MenACWY-TT (MCV4)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-TT and Tdap co-administered at Month 0 (Co-ad group)
Study: 29960800
Drug: MenACWY-TT and
Normalized name: meningococcal conjugate quadrivalent, MenACWY-TT (MCV4)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-TT and Tdap co-administered
Study: 22633362
Drug: Intravesical mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravesical mitomycin C (MMC) 40 mg/40 ml, three instillations per week for 2 weeks (group 2)
Study: 22633362
Drug: Intravesical mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravesical mitomycin C (MMC) 40 mg/40 ml, one instillation per week for 6 weeks (group 1)
Study: 17164834
Drug: In-center daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-center daily HD (1.5-2.75 h, 6 days/week)
Study: 17164834
Drug: In-center daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-center daily HD
Study: 12050241
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) at a dose of 0.005-0.010 mg/kg.d for 6 months
Study: 10760843
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution (5 mg)
Study: 10760843
Drug: Oral tablet
Normalized name: Oral Tablet
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablet formulation (5 mg)
Study: 10760843
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion (5 mg)
Study: 2147698
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate ointment 0.05%
Study: 343032
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of ibuprofen
Study: 343032
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg of ibuprofen